Ad
related to: metastatic breast cancer during pregnancy maternal and fetal outcomes in womenhealth.clevelandclinic.org has been visited by 100K+ users in the past month
Search results
Results from the WOW.Com Content Network
Docetaxel (DTX or DXL), sold under the brand name Taxotere among others, is a chemotherapy medication used to treat a number of types of cancer. [6] This includes breast cancer, head and neck cancer, stomach cancer, prostate cancer and non-small-cell lung cancer. [7] It may be used by itself or along with other chemotherapy medication. [6]
Common sites of metastasis for breast cancer. Metastatic breast cancer, also referred to as metastases, advanced breast cancer, secondary tumors, secondaries or stage IV breast cancer, is a stage of breast cancer where the breast cancer cells have spread to distant sites beyond the axillary lymph nodes. There is no cure for metastatic breast ...
The fetal origins hypothesis (differentiated from the Developmental Origins of Health and Disease hypothesis, which emphasizes environmental conditions both before and immediately after birth) proposes that the period of gestation has significant impacts on the developmental health and wellbeing outcomes for an individual ranging from infancy to adulthood.
Gestational choriocarcinoma can happen during and after any type of pregnancy event, though risk of the disease is higher in and after complete or partial molar pregnancies. [3] Risk of disease may also be higher in those experiencing pregnancy at younger or older ages that average, such as below 15 years old or above 45 years old. [4]
This is a shortened version of the eleventh chapter of the ICD-9: Complications of Pregnancy, Childbirth, and the Puerperium. It covers ICD codes 630 to 679 . The full chapter can be found on pages 355 to 378 of Volume 1, which contains all (sub)categories of the ICD-9.
Breast cancer predominantly affects women; less than 1% of those with breast cancer are men. [158] Women can develop breast cancer as early as adolescence, but risk increases with age, and 75% of cases are in women over 50 years old. [158] The risk over a woman's lifetime is approximately 1.5% at age 40, 3% at age 50, and more than 4% risk at ...
In November 2017, the European Commission authorized Ontruzant, a biosimilar from Samsung Bioepis Co., Ltd, for the treatment of early breast cancer, metastatic breast cancer and metastatic gastric cancer. [15] [16] Ontruzant is the first trastuzumab biosimilar to receive regulatory approval in the European Union. [91]
[82] [83] However, conversely, some polymorphisms show a negative association between breast size and breast cancer risk. [83] In any case, a meta-analysis concluded that breast size and risk of breast cancer are indeed importantly related. [84] Circulating IGF-1 levels are positively associated with breast volume in women. [85]
Ad
related to: metastatic breast cancer during pregnancy maternal and fetal outcomes in womenhealth.clevelandclinic.org has been visited by 100K+ users in the past month